ライフサイエンスコーパス: disappoint

1 ic transcription during development were not disappointed.

2 for acute myeloid leukemia (AML) has proved disappointing.

3 cines in phase IIa/b clinical trials remains disappointing.

4 rods and found that this approach is rather disappointing.

5 ing genes for multifactorial stroke has been disappointing.

6 whose cause is unclear and treatment remains disappointing.

7 compounds in human clinical trials has been disappointing.

8 to acetylcholinesterase inhibitors is often disappointing.

9 presenting at an advanced stage is therefore disappointing.

10 mpts to solve this problem have been largely disappointing.

11 alone in this patient group has proven to be disappointing.

12 ere developed, but clinical trials have been disappointing.

13 and the replication among studies is rather disappointing.

14 unmodified antisense RNAs has generally been disappointing.

15 d in patients with myeloma, and results were disappointing.

16 the outcome of cell transplantation remains disappointing.

17 r peripheral nerve repair in humans is often disappointing.

18 y-dwelling adults, which, to date, have been disappointing.

19 istors' power amplification ability has been disappointing.

20 hat adherence to health education advice was disappointing.

21 nism, and VEGF delivery to patients has been disappointing.

22 s with known proangiogenic factors have been disappointing.

23 sis to provide improved resolution have been disappointing.

24 ion to the diagnostic armamentarium has been disappointing.

25 us clinical trials with this agent have been disappointing.

26 t of fulminant colitis in children have been disappointing.

27 V squamous cell head and neck cancer remains disappointing.

28 urodegenerative diseases has been meager and disappointing.

29 overall survival with this approach has been disappointing.

30 in diseases where conventional DLI has been disappointing.

31 e clinical trials (oral administration) were disappointing.

32 tients with congenital corneal opacities are disappointing.

33 ment of bacterial vaginosis in pregnancy are disappointing.

34 -D monoclonal antibodies have been, at best, disappointing.

35 pancreatography pancreatitis (ERCP) has been disappointing.

36 odies and nuclear medicine imaging have been disappointing.

37 ical effectiveness of immunotherapy has been disappointing.

38 ine therapy in the adjuvant setting has been disappointing.

39 ces and antiarrhythmic drug therapy has been disappointing.

40 ablation therapy for many patients has been disappointing.

41 onists in congestive heart failure have been disappointing.

42 IDs) in the treatment of AD have so far been disappointing.

43 t, is common and the 5-year survival rate is disappointing.

44 However, results have been disappointing.

45 nventional immunosuppressive agents has been disappointing.

46 ividual genetic abnormalities have also been disappointing.

47 patients with Parkinson's disease have been disappointing.

48 cells for therapeutic applications have been disappointing.

49 infarction, and hemorrhagic shock-have been disappointing.

50 but the results for larger tumors have been disappointing.

51 The results of these trials have been disappointing.

52 e results of islet transplantation have been disappointing.

53 complex traits has been difficult and often disappointing.

54 SWL) for lower calyceal stones are generally disappointing.

55 ent of autoimmune disease in humans has been disappointing.

56 g in-stent restenosis have been consistently disappointing.

57 rts, but our results have in some cases been disappointing.

58 es, the overall impact on pathology has been disappointing.

59 s to identify the underlying genes have been disappointing.

60 eous sarcoidosis is easy, but the therapy is disappointing.

61 ts of therapy with D-penicillamine have been disappointing.

62 antioxidants have, however, been clinically disappointing.

63 treat autoimmune disease have been somewhat disappointing.

64 roblem for which medical management has been disappointing.

65 ation of this science to technology has been disappointing.

66 y the routine use of growth factors has been disappointing.

67 prognosis for advanced stage disease remains disappointing.

68 IFN protein therapy of solid tumors has been disappointing.

69 ure rates for head and neck cancer have been disappointing.

70 noclonal antilymphocyte antibodies have been disappointing.

71 fusion to clinical practice has to date been disappointing.

72 ceutical, but subsequent investigations were disappointing.

73 Pharmacological treatments were disappointing.

74 rates to therapeutic clinical trials remain disappointing.

75 sults with anti-angiogenic therapy have been disappointing.

76 , gains from second-line therapies have been disappointing.

77 sults of clinical trials have generally been disappointing.

78 cardioversion in restoring sinus rhythm was disappointing.

79 romising results, trials in humans have been disappointing.

80 cancer antigen 125 as an antigen, have been disappointing.

81 inues, the clinical return has thus far been disappointing.

82 New treatments of refractory GERD have been disappointing.

83 om a generation ago, is generally still very disappointing.

84 ancers to immune therapies has thus far been disappointing.

85 how brain processes cause consciousness are disappointing.

86 ght to drive tumor growth, results have been disappointing.

87 factor control in clinical practice has been disappointing.

88 anoma, their use in ocular variants has been disappointing.

89 Overall 5-year patient survival was a disappointing 35%.

90 s of sleep-disordered breathing have shown a disappointing ability to predict important consequences

91 ibition using sulfonylurea agents has proved disappointing, although agents acting on its pore appear

92 vitamin E supplements and cataract have been disappointing and are not yet available for selenium.

93 s to identify genetic variants have produced disappointing and contradictory results.

94 th oncogenic RAS signaling have been largely disappointing and have not resulted in meaningful clinic

95 py to inhaled corticosteroids, they are also disappointing and less effective than long-acting beta(2

96 The treatment of SLE remains disappointing and no controlled trials for neurological

97 Current treatments are disappointing and often have little beneficial effect.

98 immunosuppressive drugs has been relatively disappointing and there have been few efforts in definin

99 , clinical activity in solid tumors has been disappointing and toxicity has been a serious concern.

100 for persistent atrial fibrillation (AF) are disappointing and usually do not exceed 60%.

101 models are still widely used, but have been disappointing, and development of genetic models has giv

102 ept in the treatment of sarcoidosis has been disappointing, and may actually cause the disease.

103 ed epithelial ovarian carcinoma (EOC) remain disappointing, and the development of more effective pri

104 ted therapy for solid tumors has so far been disappointing, and the reasons for this poor response in

105 greater clinical impact than have the so far disappointing antisense endeavors.

106 tely, results from clinical trials have been disappointing as off-target effects and toxicities have

107 sis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encep

108 ials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate desi

109 of HCV treatment in this population has been disappointing because of low rates of treatment initiati

110 iences with EGFR kinase inhibitors have been disappointing, because resistance is common and tumors e

111 idual hormone/mediator have yielded somewhat disappointing body weight changes, often leading to the

112 candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns ab

113 an, interferon gamma, and relaxin) have been disappointing but new strategies against fibrosis based

114 ography has proved inconsistent and somewhat disappointing but single photon emission computed tomogr

115 icide candidates in efficacy trials has been disappointing, but next-generation concepts now in or ap

116 ediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmo

117 relish in scientific controversy will not be disappointed by the literature on the effects of sleep o

118 Considering the disappointing clinical activity of HSP90 inhibitors in o

119 targets and lead to improvement of the still disappointing clinical outcome of these patients.

120 fusion of red blood cells has been linked to disappointing clinical outcomes in the critically ill, b

121 ir stem cell function, and could explain the disappointing clinical results in many current gene tran

122 eptor (EGFR)-targeted therapies have yielded disappointing clinical results in treatment of this canc

123 E) to prevent lung cancer have produced only disappointing clinical results to date.

124 vered, perhaps an explanation for the so-far disappointing clinical translation to the prevention and

125 ouraging experimental work has led so far to disappointing clinical trials and the identification of

126 ta in humans with one agent (infliximab) but disappointing controlled data from another (etanercept).

127 c strategies that will improve the currently disappointing cure rate (approximately 25-40%) of this g

128 myocardial infarction, have provided largely disappointing data.

129 hrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored an

130 geted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM t

131 autoimmune diseases have often been notably disappointing despite many claims for linkages.

132 It disappoints despite its relatively large size, conformat

133 w antibacterial agents has been particularly disappointing, despite a plethora of potential targets,

134 poptotic receptor agonists (PARAs) have been disappointing, despite compelling preclinical efficacy w

135 ng antioxidant supplements have been equally disappointing, despite the clear benefits of a healthy d

136 ing TNF-alpha for cancer treatment have been disappointing due in part to its severe side effects, an

137 alysts, their enzymatic performance has been disappointing due to low reaction rates.

138 nisms for exercise hyperaemia are especially disappointing due to the essentially concurrent discover

139 tibodies for use as cancer vaccines has been disappointing due to the weak immunogenicity of immunogl

140 ng program implementation, results have been disappointing, e.g., only 7% of candidates passing the p

141 ith two devices have been stopped because of disappointing early results.

142 n clinical trials, MEK inhibitors have shown disappointing efficacy in mutant NRAS patients, the reas

143 s for solid-organ transplantation have shown disappointing efficacy in the prevention of chronic allo

144 Disappointing efficacy of 11betaHSD1 inhibitors in phase

145 The disappointing efficacy of blood-stage malaria vaccines m

146 ain a better understanding of the clinically disappointing EGFR-targeted therapies for GBM, we invest

147 of the tests with glans swab specimens were disappointing except for those from patients with sympto

148 ecific antisense have resulted in an overall disappointing experience.

149 nagement strategies, highlighting the rather disappointing experiences with mechanical and systemic d

150 sharp contrast to the fit-to-cohort effect, disappointing findings to date, and limited reproducibil

151 ting vasculature may, in part, explain these disappointing findings.

152 rvival and overall survival, however, remain disappointing for children with metastatic RMS at diagno

153 However, blockade of EGFR is therapeutically disappointing for gliomas with PTEN deletion.

154 neic stem cell transplantation (SCT) but are disappointing for other diseases.

155 Nothing is more disappointing for patients than when a promising new tre

156 ise as a thermal material, results have been disappointing for practical thermal systems and applicat

157 Long-term results of pericardiectomy are disappointing for some patient groups, especially those

158 initial clinical trials in humans have been disappointing, highlighting a need to optimize their imm

159 Despite a long disappointing history of human trials with neurotrophins

160 this burgeoning literature has thus far been disappointing, however, leaving open the question of whi

161 Effectiveness is then often disappointing in 'real life' conditions.

162 t in the context of atherosclerosis has been disappointing in clinical studies.

163 idual neurotrophic factors (NTF) have proved disappointing in clinical trials for neuronal repair and

164 gh increasing landscape complexity can prove disappointing in fields with low soil services or in int

165 l in a subset of patients with PPH, has been disappointing in HIV-associated pulmonary hypertension a

166 xpensive and their immunogenicity has proven disappointing in human clinical trials, we have been exp

167 disease and even promising agents have been disappointing in large-scale clinical trials.

168 Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF

169 n animal models of ALS, but have been proven disappointing in part because effective targets have not

170 However, clinical trials have been disappointing in part to dose-limiting hypercalcemia.

171 onic laryngitis, cough, and asthma have been disappointing in showing benefit of acid suppressive the

172 other hand, offer safety but have often been disappointing in terms of efficiency of nuclear delivery

173 rength composite material, it exhibits quite disappointing in terms of modulus or strength.

174 chemical compounds-for other purposes-proved disappointing in tests against Ebola virus (EBOV) infect

175 me-wide association studies (GWAS) have been disappointing in the inability of investigators to use t

176 mphoteric vectorization efforts proved to be disappointing in this series, aminoglycosidic and polyca

177 Stimulation treatments have been disappointing in vegetative state but occasionally impro

178 ognosis, particularly in advanced stages, is disappointing largely due to the resistance to conventio

179 ation for hepatocellular carcinoma have been disappointing, largely because of the high recurrence ra

180 the clinical efficacy of gene therapies were disappointing, largely because the available gene-transf

181 nts however, overall 5-year survival remains disappointing: less than 25% of patients live for 5 year

182 ) fusion F glycoprotein previously exhibited disappointing levels of RSV F immunogenicity and genetic

183 L tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typif

184 This past year has proved to be a relatively disappointing one for the development of agents that cou

185 mor necrosis factor-alpha activity have been disappointing, or of unproven benefit at best.

186 temperature (24 degrees C) have thus far had disappointing outcome results.

187 ssays, but with a precision of only 0.92%, a disappointing outcome that led to an examination of the

188 organic solar cells, although with a rather disappointing outcome to date in terms of efficiencies.

189 This disappointing outcome was traced to unfavorable pharmaco

190 lection using drug resistance genes have had disappointing outcomes and/or require highly genotoxic m

191 Such disappointing outcomes clearly call for broadening the s

192 Disappointing outcomes in clinical trials aimed at augme

193 Disappointing outcomes of nano-sized formulations (nanof

194 which immune rejection contributes to these disappointing outcomes using an immunodeficient IL2 rece

195 istent atrial fibrillation (PersAF) have had disappointing outcomes, despite concerted clinical and r

196 systemic therapies, including taxanes, yield disappointing outcomes.

197 with the RXR ligand (rexinoid) have yielded disappointing outcomes.

198 er failure of those first-line therapies are disappointing overall, with many patients eventually req

199 d targeted therapy trials have thus far been disappointing owing to a lack of robust stratification m

200 ion methods of nanowire-like devices produce disappointing performance because of process-induced mat

201 vention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with

202 wever, human trials with vitamin E have been disappointing, perhaps related to ineffective levels of

203 clinical studies of AR inhibitors have been disappointing, possibly due to poor potency in man.

204 age of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans unde

205 outcomes of somatic cell transplants remain disappointing, presumably due to lack of appropriate sup

206 A major reason for disappointing progress of psychiatric diagnostics and no

207 th attendant inflated development costs) and disappointing progress.

208 ever, progression-free survival rates remain disappointing, ranging from 40% to 50%.

209 The disappointing recent failure of fluoroquinolone-containi

210 against specific tumors have so far produced disappointing results against ovarian cancer.

211 lipoprotein (LDL) in vitro and has displayed disappointing results against the onset and development

212 Despite this, programs have yielded disappointing results and can have unintended consequenc

213 therapy with rapamycin analogues has yielded disappointing results due in part to compensatory up-reg

214 ly responsive to chemotherapy, combined with disappointing results from a recent SCLC clinical trial

215 After disappointing results from all efficacy trials conducted

216 Disappointing results from most late-stage clinical tria

217 diovascular disease paved the way to largely disappointing results from several large prevention tria

218 der in which conventional treatment leads to disappointing results in a proportion of patients.

219 DA-approved drug that has previously yielded disappointing results in clinical trials in patients wit

220 cause current pan-HDAC inhibitors have shown disappointing results in clinical trials of solid tumors

221 nation of why anti-EGFR therapies have shown disappointing results in clinical trials.

222 The disappointing results in humans should be taken as an op

223 with promising results in certain areas and disappointing results in others.

224 ion of the mismatch are also responsible for disappointing results in the application of perfusion-we

225 ation in immunologically fit individuals and disappointing results in the elderly and immunocompromis

226 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX); n

227 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX, sa

228 In contrast, oral agents have yielded disappointing results in the secondary prevention of acu

229 n infectious disease models but have yielded disappointing results in tumor models when tumor-associa

230 al limb ischemia all have contributed to the disappointing results of balloon angioplasty for complex

231 Despite the disappointing results of Explorer and Lunar trials, othe

232 This could explain the disappointing results of FGF-2 therapy in clinical trial

233 Angst over disappointing results of neuroprotection trials in Parki

234 trials, was then tempered by the subsequent disappointing results of randomized clinical trials.

235 e involving more diverse regimens, following disappointing results of retinoid monotherapy.

236 On the flip side, the disappointing results of rituximab in lupus nephritis pr

237 The disappointing results of the National Emphysema Treatmen

238 eart disease and may help explain the mostly disappointing results of this approach to date.

239 These disappointing results represent a policy failure within

240 These disappointing results stand in sharp contrast to estimat

241 ve been used in a small clinical trial, with disappointing results to date.

242 Disappointing results were announced for a number of lar

243 The disappointing results were attributed largely to poor ad

244 By contrast, disappointing results with antigen-based therapeutics hi

245 Unfortunately, there have been disappointing results with regard to improvement of tumo

246 Chemotherapy and radiation afford disappointing results, however, and novel therapies are

247 In light of these disappointing results, investigators have pursued altern

248 trials of glutamatergic modulators have had disappointing results, our growing understanding suggest

249 Despite disappointing results, two recent medication trials show

250 el mechanism-based treatments brought rather disappointing results, with low, if any, drug efficacy a

251 followed but were initially met with largely disappointing results.

252 dates, human trials have exclusively yielded disappointing results.

253 eradicate this viral reservoir have yielded disappointing results.

254 the myocardium using stem cells have yielded disappointing results.

255 mpts to improve adherence have often yielded disappointing results.

256 However, the clinical trials yielded disappointing results.

257 s of the inflammatory response, have yielded disappointing results.

258 y has been explored in myeloma patients with disappointing results.

259 ic strategies have so far yielded relatively disappointing results.

260 erapy for iliofemoral venous thrombosis with disappointing results.

261 w exceptions, empirical studies have yielded disappointing results.

262 ls with anticytokine therapies have produced disappointing results.

263 mmatory response, however, have thus far had disappointing results.

264 e candidates have been tried in humans, with disappointing results.

265 ion against virion proteins but have yielded disappointing results.

266 ter bodies but several times with unexpected disappointing results.

267 test this possibility, however, have yielded disappointing results.

268 performed for hemangiosarcoma (HAS) despite disappointing results.

269 c therapy for ischemic heart disease has had disappointing results.

270 ase (PD) have produced variable, but overall disappointing, results.

271 ted at tumor necrosis factor alpha have been disappointing so far, although preliminary studies with

272 ut their effect on clinical outcome has been disappointing so far, except for saphenous vein bypass g

273 ical trials for acute pancreatitis have been disappointing, so strategies that target and alter the b

274 While this disappointing state of affairs may suggest that plasma p

275 ease-modifying approaches have been thus far disappointing, steady advances are being made in the sym

276 in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or func

277 Disappointing survival rates from out-of-hospital cardia

278 HCT service use increased over time, it was disappointing that the proportions ever testing and ever

279 es using single targeted therapies have been disappointing, therefore providing the impetus for novel

280 What follows will disappoint those who await complaint and criticism, for

281 The results for other rTMS paradigms are disappointing thus far.

282 in efficacy and side effects that we were so disappointed to observe in recent clinical trials.

283 hase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have bee

284 lts of treatment with chemotherapy have been disappointing to date, with no trials demonstrating a be

285 hibitors targeting individual RTKs have been disappointing to date.

286 cardioprotective signaling has been largely disappointing to date.

287 usable system lasts for years." It is indeed disappointing to discover that your data resources are n

288 xplain variation in population risk had been disappointing until the advent of technologies that assa

289 r prognostic accuracy of markers often prove disappointing when "discrimination" found between cancer

290 rials of antiangiogenic strategies have been disappointing when administered as single agents, such a

291 ise in some malignancies have generally been disappointing when applied to high-grade brain tumors su

292 ocyte transplantation for cirrhosis has been disappointing when compared with laboratory experience.

293 harmaceuticals targeting this class has been disappointing, where it has been a major problem to obta

294 Women were more likely than men to be disappointed with a 20% weight loss but were less likely

295 diminishing faith in medicine (patients were disappointed with aspects of their care-seeking experien

296 les for diagnostic purposes have been rather disappointing with respect to their clinical validity, i

297 e resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suf

298 ndritic cell (DC)-based immunotherapy remain disappointing, with DCs often displaying a tenuous capac

299 n IIb/IIIa inhibition have been consistently disappointing, with evolving evidence of increased morta

300 ed aimed at the PPTg, but outcomes have been disappointing, with little evidence that gait and postur